Author:
Bazarnyi V. V.,Partylova E. A.
Abstract
Essentialy, the diagnostics feature of myeloproliferative neoplasms (MPNs) is a genetic mutations. While bcr-abl translocation belongs to CML, Jak2V617F mutation is commonly associated with other MPNs. The recent decade has been clarified a data when a human blood presents bcr-abl translocation and Jak2V617F mutation both. This clinical case reports of bcr-abl translocation and Jak2V617F mutation when they were detected simultaneously by polymerase chain reaction (PCR) in a patient with myeloproliferative neoplasm, unclassifiable (MPN-U).
Publisher
Izdatel'skii dom Spektr, LLC
Reference6 articles.
1. Heim D, Ebnöther M, Favre G. Chronische Myeloische Leukämie – Update 2020 [Chronic myeloid leukemia – update 2020]. Ther Umsch. 2019;76(9):503-9. doi: 10.1024/0040-5930/a001124
2. Ursuleac I, Colita A, Adam T, et al. The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression – an overlapping myeloproliferative disorder or two distinct diseases? – case report. J Med Life. 2013 Mar 15;6(1):34-7.
3. Chen M, Gallipoli P, DeGeer D. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1–BCR-ABL–JAK2 complex. J Natl Cancer Inst. 2013;105:405-23. doi: 10.1093/jnci/djt006
4. Yan J, Ding YW, Wang PY, et al. Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Oct;29(5):1540-7. DOI: 10.19746/j.cnki.issn
5. Soderquist CR, Ewalt MD, Czuchlewski DR, et al. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 May;31(5):690-704. DOI: 10.1038/modpathol.2017.182